Successful Early Immunosuppressive Therapy for Pulmonary Arterial Hypertension Due to Takayasu arteritis: Two Case Reports and a Review of Similar Case Reports in the English Literature

Intern Med. 2022 Jun 1;61(11):1767-1774. doi: 10.2169/internalmedicine.8095-21. Epub 2021 Nov 13.

Abstract

The efficacy of early immunosuppressive therapy without invasive therapy, such as endovascular or surgical revascularization, for pulmonary hypertension due to Takayasu arteritis (TAK-PH) remains to be elucidated. We herein report two cases of TAK-PH due to pulmonary arteritis successfully treated with early immunosuppressive therapy. A literature review of 42 cases of TAK-PH with pulmonary artery involvement showed that the cases treated with immunosuppressive therapy early after the onset (within 12 months) had a higher erythrocyte sedimentation rate and better outcome without invasive therapy than those treated later. TAK-PH may be successfully treated with immunosuppressive therapy without invasive therapy when diagnosed early with high disease activity.

Keywords: Takayasu arthritis; immunosuppressive therapy; pulmonary hypertension; revascularization.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Humans
  • Immunosuppression Therapy
  • Immunosuppressive Agents / therapeutic use
  • Pulmonary Arterial Hypertension*
  • Takayasu Arteritis* / complications
  • Takayasu Arteritis* / diagnosis
  • Takayasu Arteritis* / drug therapy
  • Vascular Surgical Procedures

Substances

  • Immunosuppressive Agents